NBIX Trading Analysis - 09/25/2026 10:16 AM — TRU-SENTIMENT

News Headlines & Context:

Recent news headlines for NBIX include:

• Neurocrine Biosciences (NBIX) announced positive topline results from their Phase 3 trial for Crinecerfont in congenital adrenal hyperplasia (CAH).
• The company reported strong quarterly earnings, beating analyst expectations and driving stock price increases.
• NBIX received FDA approval for their new treatment, expanding their portfolio and potential revenue streams.

These headlines suggest positive momentum for NBIX, driven by clinical trial successes and regulatory approvals. This could influence the technical and sentiment analysis, potentially leading to increased investor confidence and buying activity.

Fundamental Analysis:

Based on the provided fundamentals:

• Revenue: $3,373,900,000
• Trailing EPS: $6.82
• Trailing P/E: 20.37
• Debt/Equity: 0.45
• Return on Equity (ROE): 19.10%
• Operating Margins: 23.56%
• Profit Margins: 20.91%

The company shows a strong profit margin and operating margin, indicating efficient operations. The debt-to-equity ratio is moderate at 0.45. The P/E ratio of 20.37 suggests a relatively fair valuation. However, without a clear revenue growth rate or forward EPS, it's challenging to assess long-term growth prospects.

Current Market Position:

Current price: $137.54

Recent price action shows a decline, with the stock trading near its 30-day low of $137.00 and high of $160.43.

Key support levels: $137.00 (30-day low), $139.49 (recent low)

Key resistance levels: $150.83 (20-day SMA), $158.94 (50-day SMA)

Technical Analysis:

The RSI of 17.25 indicates oversold conditions, which could lead to a bounce. The MACD at -5.28 suggests bearish momentum. The stock is below both the 20-day and 50-day SMAs, indicating a downtrend.

True Sentiment Analysis (Delta 40-60 Options):

Options sentiment is bullish, with a call dollar volume of $350.00 and 0% put dollar volume.

The pure directional positioning suggests near-term bullish expectations.

Key Price Levels:

• Support: $137.00, $139.49
• Resistance: $150.83, $158.94

These levels could act as barriers or targets for price movements.

25-Day Price Forecast:

Based on current trends:

• RSI momentum suggests potential for recovery
• MACD indicates bearish trend
• ATR (14): 3.98

NBIX is projected for $132.10 to $145.20 in 25 days, considering the oversold RSI, current support levels, and resistance barriers.

Defined Risk Strategy Recommendations:

Based on the forecast ($132.10 to $145.20) and option chain:

• Bull Call Spread: Buy 135C (bid: $4.8, ask: $7.5) and Sell 140C (bid: $2.3, ask: $3.5) expiring 10/16, cost: $2.5-$4.2
• Bear Put Spread: Buy 130P (bid: $0, ask: $2.15) and Sell 135P (bid: $1.7, ask: $3.9) expiring 10/16, cost: $1.15-$2.15
• Iron Condor: Sell 130P (bid: $0, ask: $2.15) and Sell 140C (bid: $2.3, ask: $3.5), Buy 125P (bid: $0, ask: $2.9) and Buy 145C (bid: $0.5, ask: $4.1) expiring 10/16

These strategies align with the projected price range and offer defined risk.

Risk Factors:

• Technical warning signs: RSI oversold, but MACD bearish
• Sentiment divergences: Bullish options flow vs bearish technicals
• Volatility: ATR 3.98 indicates moderate volatility

Monitoring these factors could invalidate the thesis.

Summary & Conviction Level:

Overall bias: Neutral

Conviction level: Medium

One-line trade idea: Consider defined risk strategies aligning with technical and sentiment analysis.